Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06712823 · ClinicalTrials.gov registry record · Phase 2
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
A Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia, sponsored by Crinetics Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 9
- Study locations
NCT06712823: Recruiting Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia, sponsored by Crinetics Pharmaceuticals.
NCT06712823 is a Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia that is actively recruiting participants, run by Crinetics Pharmaceuticals. The registered enrollment target is 150 participants, above the 84-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (79% higher). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06712823, a Phase 2 study of Congenital Adrenal Hyperplasia and Classic Congenital Adrenal Hyperplasia, is actively recruiting participants, sponsored by Crinetics Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).
Conditions Studied
Interventions
- DRUG atumelnant (CRN04894)
Study Locations (9)
Other
- Crinetics Study Site - São Paulo
- Crinetics Study Site - Roma
- Crinetics Study Site - Birmingham
- Crinetics Study Site - London
Minnesota
- Crinetics Study Site, Minneapolis, Minnesota 55454 - Minneapolis
North Carolina
- Crinetics Study Site - Morehead City
Córdoba Province
- Crinetics Study Site - Córdoba
São Paulo
- Crinetics Study Site - Botucatu
Bavaria
- Crinetics Study Site - Munich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What NCT06712823 shows while recruiting
NCT06712823 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 84-participant average among 8 other Congenital Adrenal Hyperplasia trials with a reported enrollment target (79% higher).
The record links to 2 conditions, with Congenital Adrenal Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which atumelnant (CRN04894) is the first listed.
NCT06712823 lists 9 locations in 6 states (Other, Minnesota, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06712823 about?
NCT06712823 is a clinical study titled "An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894". The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).
What is the current status of trial NCT06712823?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-02-25. Estimated completion is 2027-11.
What conditions does trial NCT06712823 study?
This clinical trial studies the following conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia.
What interventions are being tested in trial NCT06712823?
The interventions under investigation include: atumelnant (CRN04894) (DRUG).
Who is sponsoring clinical trial NCT06712823?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06712823 being conducted?
This trial has 9 study locations across Minnesota, North Carolina, Córdoba Province, São Paulo, Bavaria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Adrenal Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06712823's enrollment target sits among peer trials
150 3rd of 8 higher than 5 of 8 other Congenital Adrenal Hyperplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Congenital Adrenal Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
RECRUITING · Phase 2
-
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
COMPLETED · Phase 2
-
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
RECRUITING · Phase 1
-
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
RECRUITING · Phase 3
-
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)
ACTIVE NOT RECRUITING · Phase 1
-
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI